News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Roche Ready to Walk Away From $6.8 Billion Illumina Bid
April 18, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(Reuters) - Roche might be better off dropping its $6.80 billion bid for genomics specialist Illumina and coming back a year later, as its legacy of paying up after protracted takeovers has damaged its bargaining power, some bankers believe.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Mergers & acquisitions
Europe
Illumina, Inc.
Roche
MORE ON THIS TOPIC
Manufacturing
Sun Pharma recalls cancer drug after finding glass particles in some vials
May 15, 2026
·
2 min read
·
Nick Paul Taylor
Drug Development
Biogen’s Alzheimer’s results bolster tau theory—and Denali’s next gen candidate
May 15, 2026
·
3 min read
·
Annalee Armstrong
Series B
CREATE jumps into CAR T competition with $122M series B
May 15, 2026
·
2 min read
·
Tristan Manalac
Funding
Degron adds $40M to series A, supporting immunology plans for molecular glue platform
May 14, 2026
·
2 min read
·
Tristan Manalac